{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-284609","form_type":"8-K","ticker":"IONS","cik":"0000874015","company_name":"IONIS PHARMACEUTICALS INC","filed_at":"2025-11-17T23:59:59+00:00","discovered_at":"2026-05-14T18:02:42.421959+00:00","generated_at":"2026-05-16T19:34:27.231107+00:00","sec_items":["1.01","2.03","3.02","8.01","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Ionis closes $770M 0% convertible notes offering, repurchases $200M of 2026 notes","bullets":["Issued $770M aggregate principal of 0.00% Convertible Senior Notes due 2030 (including full greenshoe), net proceeds ~$751.2M.","Used ~$267.6M of net proceeds to repurchase $200M of existing 2026 convertible notes via concurrent transactions.","Remaining proceeds for further repurchases of 2026 notes and general corporate purposes.","Initial conversion rate: 10.1932 shares/$1,000, conversion price ~$98.10 (35% premium over Nov 12 close of $72.67).","Notes mature Dec 1, 2030, no regular interest, redeemable after Dec 6, 2028 if stock ≥130% of conversion price."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-284609","json":"https://secwatch.observer/filing/0001193125-25-284609.json","markdown":"https://secwatch.observer/filing/0001193125-25-284609.md","text":"https://secwatch.observer/filing/0001193125-25-284609.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/874015/000119312525284609/0001193125-25-284609-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/874015/000119312525284609/d31230d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T19:34:27.231107+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2f7e32fea50ebb81283ab851bd919d0d824eadba","claim":"IONIS PHARMACEUTICALS INC incurred convertible notes of $770.0 million aggregate principal amount with U.S. Bank Trust Company, National Association at 0.00% maturing December 1, 2030.","evidence_excerpt":"On November 17, 2025, Ionis Pharmaceuticals, Inc. (the “Company”) completed its previously announced private offering (the “Offering”) of $770.0 million aggregate principal amount of 0.00% Convertible Senior Notes due 2030 (the “Notes”), including the exercise in full of the initial purchasers’ option to purchase up to an additional $70.0 million principal amount of Notes.","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/874015/000119312525284609/0001193125-25-284609-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"convertible notes"},{"label":"Principal","value":"$770.0 million aggregate principal amount"},{"label":"Counterparty","value":"U.S. Bank Trust Company, National Association"},{"label":"Rate","value":"0.00%"},{"label":"Maturity","value":"December 1, 2030"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"104f5e8bb811ff2605c88143a4b7e6a3193c44be","claim":"IONIS PHARMACEUTICALS INC issued convertible note to initial purchasers for $770.0 million aggregate principal amount.","evidence_excerpt":"On November 17, 2025, Ionis Pharmaceuticals, Inc. (the “Company”) completed its previously announced private offering (the “Offering”) of $770.0 million aggregate principal amount of 0.00% Convertible Senior Notes due 2030 (the “Notes”), including the exercise in full of the initial purchasers’ option to purchase up to an additional $70.0 million principal amount of Notes.","evidence_source":"SEC 8-K Item 3.02/3.03","evidence_url":"https://www.sec.gov/Archives/edgar/data/874015/000119312525284609/0001193125-25-284609-index.htm","confidence":0.9,"family_label":"Equity Issuances","details":[{"label":"Security","value":"convertible note"},{"label":"Purchaser","value":"initial purchasers"},{"label":"Consideration","value":"$770.0 million aggregate principal amount"}],"fact_type":"equity_issuance"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}